International, Multi-center, Open Label, 9-month Follow-up Extension Study Assessing the Long-term Safety and Tolerability of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A

Trial Profile

International, Multi-center, Open Label, 9-month Follow-up Extension Study Assessing the Long-term Safety and Tolerability of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A

Recruiting
Phase of Trial: Phase III

Latest Information Update: 09 May 2018

At a glance

  • Drugs Baclofen/naltrexone/sorbitol (Primary)
  • Indications Charcot-Marie-Tooth disease
  • Focus Adverse reactions
  • Acronyms PLEO-CMT-FU
  • Sponsors Pharnext
  • Most Recent Events

    • 12 Apr 2018 According to a Pharnext media release, initial results from this study are expected in the second quarter of 2019.
    • 02 Jan 2018 Planned End Date changed from 1 Jan 2019 to 1 Oct 2019.
    • 02 Jan 2018 Planned primary completion date changed from 1 Jan 2019 to 1 Sep 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top